Education and Training
Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
To measure how frequently and to what degree a complication of transplant cell acute graft versus host disease (GvHD) occurs.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: cyclosporine
- drug: Anti-thymocyte globulin (ATG)
- drug: Mycophenolate mofetil (MMF)
- drug: Filgrastim
- radiation: Total Lymphoid Irradiation (TLI)
Eligibility
INCLUSION CRITERIA:
- Any patient with one of the following hematolymphoid malignancies or syndromes in whom
allogeneic hematopoietic stem cell transplant (HST) is warranted. Specific disease
categories include:
- Indolent advanced stage non-Hodgkin lymphomas
- Mantle cell lymphoma
- Chronic lymphocytic leukemia
- Hodgkin disease (Hodgkin's lymphoma)
- Acute leukemias in complete remission
- Aplastic anemia
- Paroxysmal nocturnal hemoglobinuria
- Myelodysplastic or myeloproliferative syndromes.
- Other selected malignancies/disorders may also be considered but must be approved
by the transplant team and the Principal Investigator.
- Age > 50 years, or if < 50 years of age, considered to be at high risk for
regimen-related toxicity associated with conventional myeloablative transplants due to
pre-existing medical conditions or prior therapy.
- A fully human leukocyte antigen (HLA)-identical sibling or matched unrelated donor is
available. Potential participants with one antigen mismatched donors can be considered
but only after discussion with the transplant team and the Principal Investigator.
- Participant must be competent to give consent.
EXCLUSION CRITERIA:
- Progressive hematolymphoid malignancies despite conventional therapies, or acute
leukemias not in complete remission.
- Uncontrolled central nervous system (CNS) involvement with disease
- Fertile men or women unwilling to use contraceptive techniques during and for 12
months following treatment
- Pregnant
- Cardiac ejection fraction < 30%
- Uncontrolled cardiac failure
- Pulmonary diffusing capacity (DLCO) < 40% predicted
- Elevation of bilirubin to > 3 mg/dL
- Transaminases > 4 x the upper limit of normal
- Creatinine clearance < 50 cc/min (24-hour urine collection)
- Karnofsky performance score < 60%
- Poorly controlled hypertension on multiple antihypertensives
- Documented fungal disease that is progressive despite treatment
- HIV-positive. Other viral infections, ie, Hepatitis B- and C- positive, evaluated on a
case-by-case basis
- Psychiatric disorders or psychosocial problems which in the opinion of the primary
physician or Principal Investigator would place the patient at unacceptable risk from
this regimen.
Ages Eligible for Study
50 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Physician Referrals
650-723-0822
Not Recruiting